On January 5, 2026, Zenas BioPharma announced Phase 3 results for obexelimab in IgG4-related disease. The drug hit its primary endpoint — a 56% reduction in flare risk. The stock lost more than half its value in a single session.
On January 7, CEO Leon Moulder started buying.
He hasn't stopped.
The Efficacy Debate
The market's logic was simple. Amgen's Uplizna — the first FDA-approved treatment for IgG4-RD — showed an 87% reduction in flare risk. Obexelimab showed 56%. Jefferies had publicly set the bar at 65% for "commercial viability." Below that line, the market decided the drug was dead.
But there are things the headline number doesn't capture. Obexelimab doesn't deplete B cells — it inhibits them. That distinction matters for long-term safety, particularly infection rates, which ran lower than placebo in the INDIGO trial. It's subcutaneous, not IV. And the IgG4-RD population isn't one-size-fits-all — a non-depleting option with a cleaner safety profile has a clinical rationale that a single hazard ratio doesn't reflect.
The insiders seem to agree.
The Buying
Three distinct insiders. Three months. Escalating size. Here's the chronology:
| Date | Insider | Role | Shares | Avg Price | Value |
|---|---|---|---|---|---|
| Jan 7 | Leon Moulder | CEO | 50,000 | $16.38 | $819K |
| Jan 8 | Leon Moulder | CEO | 30,000 | $16.30 | $489K |
| Jan 9 | Leon Moulder | CEO | 20,000 | $16.55 | $331K |
| Feb 11 | Hongbo Lu / NEXTBio | Director | 25,985 | $22.50 | $585K |
| Feb 13 | Patricia Allen | Director | 4,160 | $26.36 | $110K |
| Mar 30 | Leon Moulder | CEO | 20,000 | $18.23 | $365K |
| Mar 31 | Leon Moulder | CEO | 34,000 | $19.31 | $657K |
| Mar 31 | Hongbo Lu / NEXTBio | Director | 78,768 | ~$19.90 | $1.57M |
| Mar 31 | Fairmount Funds | Director | 150,000 | $20.00 | $3.00M |
This isn't a one-time bet. Moulder bought on three consecutive days in January, within 48 hours of the crash. Then he came back in March and bought again — at higher prices than his January entries. Hongbo Lu's affiliated entity NEXTBio has accumulated over $7 million in total across the period. Fairmount Funds — a director-affiliated healthcare specialist — dropped $3 million in a single transaction on March 31.
The stock was at $22.12 when the latest filings hit. It's up 7.6% on the disclosure alone.
The Divergence
This is what a market disagreement looks like in Form 4 data:
Six of seven covering analysts rate ZBIO Buy or Outperform. The median price target is $44 — more than double the current price. Guggenheim and Evercore are at $55. Only Morgan Stanley, at $21 (Equal-Weight), sides with the bears.
The Setup
The BLA submission to the FDA is expected within weeks — Q2 2026. If accepted, a potential approval in H1 2027. The company just raised $300 million in March (convertible notes + equity offering), giving it runway through a potential launch. The cash position eliminates the "will they survive to approval" question that kills most small-cap biotech signals.
The addressable market — IgG4-related disease — has roughly 57,000 diagnosed prevalent cases in the US, growing. It's not a blockbuster market by oncology standards. But it's real, it's growing at a 34% CAGR, and there's room for a second entrant with a differentiated safety profile. Uplizna depletes B cells. Obexelimab doesn't. That's not a subtle distinction for a chronic autoimmune condition where patients may be on therapy for years.
Signal Assessment
Confidence: High
Three independent insiders. Eleven-plus transactions over three months. Zero sells. CEO buying on consecutive days immediately after a 55% crash — that's not a governance signal, that's personal conviction with personal capital. The $3 million single-transaction Fairmount buy on March 31 is the cluster's capstone. Combined with BLA weeks away, $300M freshly raised, and an analyst consensus target at 2x current price, this is one of the cleanest insider divergence patterns in small-cap biotech this quarter.
Tickers mentioned: ZBIO (Zenas BioPharma), AMGN (Amgen/Uplizna). Catalysts: BLA submission Q2 2026, Phase 2 SLE data Q4 2026. Noise floor: The 56% vs 87% efficacy gap is real. Uplizna has first-mover advantage. The $100M equity offering diluted existing shareholders. This is a divergence signal, not a guarantee — insiders can be wrong, especially in biotech. But they rarely put $16.5 million behind a drug they think is dead.